ESR1 and breast carcinoma: Despite initial positive outcomes observed for many ERα + breast cancers, between 40 and 50% of patients receiving endocrine therapy acquire resistance after five or more years of treatment, ultimately leading to relapse, metastatic disease and death (Anurag et al., 2018).